Serum Biomarkers Identify Patients Who Will Develop Inflammatory Bowel Diseases Up to 5 Years Before Diagnosis.


Journal

Gastroenterology
ISSN: 1528-0012
Titre abrégé: Gastroenterology
Pays: United States
ID NLM: 0374630

Informations de publication

Date de publication:
07 2020
Historique:
received: 09 12 2019
revised: 07 02 2020
accepted: 02 03 2020
pubmed: 14 3 2020
medline: 1 4 2021
entrez: 14 3 2020
Statut: ppublish

Résumé

Biomarkers are needed to identify patients at risk for development of inflammatory bowel diseases. We aimed to identify serum biomarkers of Crohn's disease and ulcerative colitis that can be detected and quantified before diagnosis. We obtained serum samples from patients archived before a diagnosis of Crohn's disease (n = 200) or ulcerative colitis (n = 199), as well as from 200 healthy individuals (controls), collected from 1998 through 2013 as part of the US Defense Medical Surveillance System. We measured levels of antibodies against microbes (anti-Saccharomyces cerevisiae IgA or IgG, anti-Escherichiacoli outer membrane porin C, anti-CBir1, anti-flagellin 2, anti-flagellin X, and perinuclear anti-neutrophil cytoplasmic antibodies) and 1129 proteins in each sample. We then used functional principal component analysis to derive the time-varying trajectory for each marker, which then was used in a multivariate model to predict disease status. Predictive performances at different prediagnosis timepoints were evaluated using area under the receiver operating characteristic curves (AUROCs). Biological pathways that were up-regulated in serum from patients with Crohn's disease were identified based on changes in protein abundance at different time periods preceding diagnosis. We identified a panel of 51 protein biomarkers that were predictive of Crohn's disease within 5 years with an AUROC of 0.76 and a diagnosis within 1 year with an AUROC of 0.87. Based on the proteins included in the panel, imminent development of CD was associated with changes in the complement cascade, lysosomes, innate immune response, and glycosaminoglycan metabolism. Serum antibodies and proteins identified patients who received a diagnosis of ulcerative colitis within 5 years with an AUROC of only 0.56 and within 1 year with an AUROC of 0.72. We identified a panel of serum antibodies and proteins that were predictive of patients who will receive a diagnosis of Crohn's disease within 5 years with high accuracy. By contrast we did not identify biomarkers associated with future diagnosis of ulcerative colitis.

Sections du résumé

BACKGROUND & AIMS
Biomarkers are needed to identify patients at risk for development of inflammatory bowel diseases. We aimed to identify serum biomarkers of Crohn's disease and ulcerative colitis that can be detected and quantified before diagnosis.
METHODS
We obtained serum samples from patients archived before a diagnosis of Crohn's disease (n = 200) or ulcerative colitis (n = 199), as well as from 200 healthy individuals (controls), collected from 1998 through 2013 as part of the US Defense Medical Surveillance System. We measured levels of antibodies against microbes (anti-Saccharomyces cerevisiae IgA or IgG, anti-Escherichiacoli outer membrane porin C, anti-CBir1, anti-flagellin 2, anti-flagellin X, and perinuclear anti-neutrophil cytoplasmic antibodies) and 1129 proteins in each sample. We then used functional principal component analysis to derive the time-varying trajectory for each marker, which then was used in a multivariate model to predict disease status. Predictive performances at different prediagnosis timepoints were evaluated using area under the receiver operating characteristic curves (AUROCs). Biological pathways that were up-regulated in serum from patients with Crohn's disease were identified based on changes in protein abundance at different time periods preceding diagnosis.
RESULTS
We identified a panel of 51 protein biomarkers that were predictive of Crohn's disease within 5 years with an AUROC of 0.76 and a diagnosis within 1 year with an AUROC of 0.87. Based on the proteins included in the panel, imminent development of CD was associated with changes in the complement cascade, lysosomes, innate immune response, and glycosaminoglycan metabolism. Serum antibodies and proteins identified patients who received a diagnosis of ulcerative colitis within 5 years with an AUROC of only 0.56 and within 1 year with an AUROC of 0.72.
CONCLUSIONS
We identified a panel of serum antibodies and proteins that were predictive of patients who will receive a diagnosis of Crohn's disease within 5 years with high accuracy. By contrast we did not identify biomarkers associated with future diagnosis of ulcerative colitis.

Identifiants

pubmed: 32165208
pii: S0016-5085(20)30327-9
doi: 10.1053/j.gastro.2020.03.007
pii:
doi:

Substances chimiques

Antibodies, Antineutrophil Cytoplasmic 0
Antibodies, Bacterial 0
Antibodies, Fungal 0
Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

96-104

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020 AGA Institute. All rights reserved.

Auteurs

Joana Torres (J)

Department of Medicine, Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York; Gastroenterology Division, Hospital Beatriz Ângelo, Loures, Lisbon, Portugal.

Francesca Petralia (F)

Department of Genetics and Genomic Sciences, Icahn School of Medicine, New York City, New York.

Takahiro Sato (T)

Janssen Research and Development, Spring House (Ambler), Pennsylvania.

Pei Wang (P)

Department of Genetics and Genomic Sciences, Icahn School of Medicine, New York City, New York.

Shannon E Telesco (SE)

Janssen Research and Development, Spring House (Ambler), Pennsylvania.

Rok Seon Choung (RS)

Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.

Richard Strauss (R)

Janssen Research and Development, Spring House (Ambler), Pennsylvania.

Xiao-Jun Li (XJ)

Prometheus Laboratories, San Diego, California.

Renee M Laird (RM)

Enteric Diseases Department, Naval Medical Research Center, Silver Spring, Maryland.

Ramiro L Gutierrez (RL)

Enteric Diseases Department, Naval Medical Research Center, Silver Spring, Maryland.

Chad K Porter (CK)

Enteric Diseases Department, Naval Medical Research Center, Silver Spring, Maryland.

Scott Plevy (S)

Janssen Research and Development, Spring House (Ambler), Pennsylvania.

Fred Princen (F)

Prometheus Laboratories, San Diego, California.

Joseph A Murray (JA)

Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.

Mark S Riddle (MS)

Enteric Diseases Department, Naval Medical Research Center, Silver Spring, Maryland; Department of Preventive Medicine and Biostatistics, Uniformed Services University, Bethesda, Maryland. Electronic address: markriddlemd@gmail.com.

Jean-Frederic Colombel (JF)

Department of Medicine, Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: jean-frederic.colombel@mssm.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH